Monopar Therapeutics Inc. (MNPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Monopar Therapeutics Inc. on August 30, 2023, regarding an event dated August 28, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Wilmette, Illinois. Its common stock trades on The Nasdaq Capital Market under the symbol "MNPR."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On August 28, 2023, the Company received a notice from Nasdaq stating that its common stock had closed below the minimum $1.00 per share bid price requirement for 30 consecutive business days. This deficiency violates Nasdaq Listing Rule 5550(a)(2). The stock continues to trade on Nasdaq pending compliance actions.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending February 26, 2024, to regain compliance.
- Regaining Compliance: Compliance is achieved if the bid price closes at $1.00 or more for 10 consecutive business days before the compliance deadline.
- Second Compliance Period: If the initial period is unsuccessful, the Company may qualify for a second 180-day period, provided it meets all other initial listing standards (excluding the bid price) and the market value of publicly held shares requirement.
- Delisting Risk: Failure to regain compliance during the second period will result in a delisting notice. The Company may appeal this determination to the Nasdaq Hearings Panel, though success is not assured.
- Management Commentary: Management stated it will monitor the closing bid price and seek to regain compliance but offered no assurance that it will succeed within the allotted timeframes.
Key Facts for Investor Verification
- Verify the current closing bid price of MNPR stock to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward the February 26, 2024, compliance deadline.
- Review future filings for any announcements regarding a second compliance period or delisting notices.
- Check the Company's market value of publicly held shares to determine eligibility for a second compliance period if needed.